Company
New medicines, proven on virtual patients first
We are building the simulation layer every drug programme runs before, and alongside, its physical trials, so development gets faster, safer and fairer to the people trials leave out.
Why we started
Too many trials fail on choices made too early
Clinical trials are the slowest and most expensive step in drug development, and most fail. Often the cause is a choice made before the first patient enrolled: a dose, an inclusion criterion, an endpoint.
Those choices are made with thin, biased history. Groups that matter, from children to under-represented ancestries, are often missing entirely. We started Sanenza to let teams test those choices on realistic virtual populations first, and to keep an honest record of how well the simulations predicted what happened next.
Principles
How we work
Evidence
Check every claim
A prediction is a claim until it is compared with an outcome.
Equity
Simulate the people trials miss
Rare and under-represented groups are a design input, not an afterthought.
Restraint
Say what we cannot do
Our reports state their limits in plain words.
Roadmap
Draft roadmap
Plans, not commitments. Dates depend on design partners.
| When | Milestone |
|---|---|
| 2026 | Platform core: Cohorta, Insilon and Evidra in development |
| 2027 H1 | First design-partner pilots in one or two therapeutic areas |
| 2027 H2 | Protova and Vigila in pilots; private cloud deployment |
| 2028 | Physova pilots; wider therapeutic-area coverage |
Careers
Open roles
Draft openings. Write to careers@sanenza.com with the role in the subject line.
Stack
What we build with
Help prove medicines on virtual patients first
If you work on pharmacology, machine learning or regulatory science, we would like to hear from you.